TY  - GEN
AU  - Ghofrani,Hossein-Ardeschir
AU  - Simonneau,Gérald
AU  - D'Armini,Andrea M
AU  - Fedullo,Peter
AU  - Howard,Luke S
AU  - Jaïs,Xavier
AU  - Jenkins,David P
AU  - Jing,Zhi-Cheng
AU  - Madani,Michael M
AU  - Martin,Nicolas
AU  - Mayer,Eckhard
AU  - Papadakis,Kelly
AU  - Richard,Dominik
AU  - Kim,Nick H
TI  - Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
SN  - 2213-2619
PY  - 2018///0605
KW  - Aged
KW  - Chronic Disease
KW  - Double-Blind Method
KW  - Endothelin Receptor Antagonists
KW  - administration & dosage
KW  - Female
KW  - Humans
KW  - Hypertension, Pulmonary
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Natriuretic Peptide, Brain
KW  - drug effects
KW  - Peptide Fragments
KW  - Pulmonary Embolism
KW  - Pyrimidines
KW  - Sulfonamides
KW  - Treatment Outcome
KW  - Vascular Resistance
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Retracted Publication
UR  - https://doi.org/10.1016/S2213-2600(17)30305-3
ER  -